Trial Profile
A Phase IV, Single-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study on the Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Individuals With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EmDia
- 01 Jul 2023 Primary endpoint has been met. (difference in E/E ratio between 12 weeks after baseline and at baseline), as per Results published in the Clinical Research in Cardiology
- 01 Jul 2023 Results published in the Clinical Research in Cardiology
- 11 Sep 2020 Status changed from recruiting to completed.